Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 3, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 2,150,000 ordinary shares of 25 pence each.
- Purchase Price: 1,121.82 pence per share.
- Total Transaction Value: Approximately £24.12 million (calculated from share count and price).
Material Changes
Following the cancellation of the repurchased shares, the company's capital structure was updated as follows:
- Treasury Shares: The company now holds 484,194,158 shares in Treasury, representing 8.94% of total voting rights.
- Shares in Issue: There are 5,415,298,596 shares in issue (excluding Treasury shares), which represents the total voting rights in the company.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,415,298,596) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on the total voting rights denominator.
- Note that this filing is a notification of a completed share cancellation and does not contain operational or financial performance data for the period.